TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

Edesa Biotech (EDSA) announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred ...

As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with ...

Dr. Pardeep Nijhawan ("Dr. Nijhawan") and Velan Capital jointly announce updates to their beneficial ownership of securities of Edesa Biotech, Inc. ("Edesa") in accordance with "early warning" ...

TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...

Lakeside Holding Limited ("Lakeside" or the "Company") , a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...